Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 12, 2007 - Issue 3
Submit an article Journal homepage
103
Views
11
CrossRef citations to date
0
Altmetric
Review

Emerging therapeutic agents for onychomycosis

Gérald E Piérard CHU Sart Tilman, Department of Dermatopathology, B-4000 Liège, Belgium [email protected]
,
Jorge E Arrese CHU Sart Tilman, Department of Dermatopathology, B-4000 Liège, Belgium [email protected]
,
Pascale Quatresooz CHU Sart Tilman, Department of Dermatopathology, B-4000 Liège, Belgium [email protected]
&
C PiÉrard-Franchimont CHU Sart Tilman, Department of Dermatopathology, B-4000 Liège, Belgium [email protected]
Pages 345-353 | Published online: 17 Sep 2007

Bibliography

  • GHANNOUM MA, HAJJEH RA, SCHER R et al.: A large-scale North American study of fungi isolated from nails: the frequency of onychoycosis, fungal distribution, and antifungal susceptibility patterns. J. Am. Acad. Dermatol. (2000) 43:641-648.
  • GUPTA AK, JAIN HC, LYNDE CW et al.: Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J. Am. Acad. Dermatol. (2000) 43:244-248.
  • PIERARD GE: Onychomycosis and other superficial fungal infections on the foot in the elderly: a pan European survey. Dermatology (2001) 202:220-224.
  • BURZYKOWSKI T, MOLENBEGHS G, ABECK D et al.: High prevalence of foot diseases in Europe: results of the Achilles project. Mycoses (2003) 46:496-505.
  • TOSTI A, PIRACCINI BM, MARIANI R et al.: Are local and systemic conditions important for the development of onychomycoses. Eur. J. Dermatol. (1998) 1:41-44.
  • SIGURGEIRSSON B, STEINGRIMSSON O: Risk factors associated with onychomycosis. J. Eur. Acad. Dermatol. Venereol. (2004) 18:48-51.
  • GUPTA AK, HUMKE S: The prevalence and management of onychomycosis in diabetic patients. Eur. J. Dermatol. (2000) 10:379-384.
  • PIERARD GE, PIERARD-FRANCHIMONT C: The nail under fungal siege in patients with Type II diabetes mellitus. Mycoses (2005) 48:339-342.
  • GUPTA AK, LYNDE CW, JAIN HC et al.: A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br. J. Dermatol. (1997) 136:786-789.
  • LARSEN GK, HAEDERSDAL M, SVEJGAARD EL: The prevalence of onychomycosis in patients with psoriasis and other skin diseases. Acta Derm. Venereol. (2003) 83:206-209.
  • PIERARD-FRANCHIMONT C, ARRESE JE, HERMANNS-Lê T, PIERARD GE: Epidemiology of onychomycosis assessed by histomycology in psoriatic patients. J. Mycol. Med. (2006) 16:159-162.
  • PIERARD GE, ARRESE JE, PIERARD-FRANCHIMONT C, QUATRESOOZ P: Onychomycosis in older patient. Aging Health (2006) 2:865-870.
  • PIERARD-FRANCHIMONT C, ARRESE JE, QUATRESOOZ P, PIERARD GE: Mycopsoriatic onychopathy. Rev. Med. Liège (In press).
  • GUPTA AK, GUPTA MA, SUMMERBELL RC et al.: The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J. Eur. Acad. Dermatol. Venereol. (2000) 14:466-469.
  • SAEZ DE OCARIZ M, ARENAS R, RANERO-JUAREZ GA: Frequency of toenail onychomycosis in patients with cutaneous manifestations of chronic venous insufficiency. Int. J. Dermatol. (2001) 40:18-25.
  • PIERARD GE: Spores, sporodochia and fomites in onychomycosis. Dermatology (2006) 213:169-172.
  • ARRESE JE, PIERARD-FRANCHIMONT C, PIERARD GE: Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient. Am. J. Dermatpathol. (1996) 18:196-198.
  • NUCCI M, ANAISSIE E: Cutaneous infections by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin. Infect. Dis. (2002) 35:909-920.
  • QUATRESOOZ P, PIERARD-FRANCHIMONT C, ARRESE JE, PIERARD GE: Clinico-pathological presentations of dermatomycosis in cancer patients. J. Eur. Acad. Dermatol. Venereol. (In press).
  • ARRESE JE, PIERARD-FRANCHIMONT C, PIERARD GE: A plea to bridge the gap between antifungals and onychomycosis management. Am. J. Clin. Dermatol. (2001) 2:281-284.
  • ARRESE JE, PIERARD GE: Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology (2003) 207:255-260.
  • POTTER LP, MATHIAS SD, RAUT M, KIANIFARD F, LANDSMAN A, TAVAKKOL A: The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. Dermatol. Treat. (2007) 18:46-52.
  • MUKHERJEE PK, LEIDICH SD, ISHAM I, LEITNER I, RYDER NS, GHANNOUM MA: Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob. Agents Chemother. (2003) 47:82-86.
  • FAVRE B, GHANNOUM MA, RYDER NS: Biochemical characterization of terbinafine-resistant Trichophyton rubrum isolates. Med. Mycol. (2004) 42:525-529.
  • BORGERS M, DEGREEF H, CAUWENBERGH G: Fungal infections of the skin: infection process and antimycotic therapy. Curr. Drug Targets (2005) 6:849-862.
  • MURDAN S: Drug delivery to the nail following topical application. Int. J. Pharmaceutics (2002) 236:1-26.
  • FLAGOTHIER C, PIERARD-FRANCHIMONT C, PIERARD GE: New insights in the effect of amorolfine nail lacquer. Mycoses (2005) 48:91-94.
  • ARRESE JE, DE DONCKER P, ODDS F, PIERARD GE: Reduction in the growth of non-dermatophyte moulds by itraconazole: evaluation by corneofungimetry bioassay. Mycoses (1998) 41:461-465.
  • OSBORNE CS, LEITNER I, FAVRE B, RYDER NS: Antifungal drug response in an in vitro model of dermatophyte nail infection. Med. Mycol. (2004) 42:159-163.
  • BARAN R, GUPTA AK, PIERARD GE: Pharmacotherapy of onychomycosis. Expert Opin. Pharmacother. (2005) 6:609-624.
  • PIERARD GE, PIERARD-FRANCHIMONT C, VROOME V, BORGERS M, CAUWENBERGH G: Established and emerging oral antifungals in dermatology. In: Dermatological and Cosmeceutical Development. Walters KA, Roberts MS (Eds), Publ. Marcel Dekker, New York, USA (In press).
  • PIERARD GE, ARRESE JE, PIERARD-FRANCHIMONT C: Treatment of onychomycosis. Traditional approaches. J. Am. Acad. Dermatol. (1993) 29:S41-S45.
  • DEGREEF H, HEERES J, BORGERS M: Antifungal azoles for skin disorders. Expert Opin. Ther. Patents (2006) 16:1235-1253.
  • PIERARD GE, ARRESE JE, DE DONCKER P: Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J. Am. Acad. Dermatol. (1995) 32:429-435.
  • PIERARD GE, ARRESE JE, PIERARD-FRANCHIMONT C: Itraconazole. Exp. Opin. Pharmacother. (2000) 1:287-304.
  • ARRESE JE, PIERARD-FRANCHIMONT C, PIERARD GE: Facing up to the diagnostic uncertainty and management of onychomycoses. Int. J. Dermatol. (1999) 38:S1-S6.
  • PIERARD GE, PIERARD-FRANCHIMONT C, ARRESE JE: The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology (2000) 200:185-187.
  • PIERARD GE, PIERARD-FRANCHIMONT C, ARRESE JE: The boosted antifungal topical treatment (BATT) for onychomycosis. Med. Mycol. (2000) 38:391-392.
  • GUPCHUP GV, ZATZ JL: Structural characteristics and permeability properties of the human nail: a review. J. Cosmet. Sci. (1999) 50:363-385.
  • KOBAYASHI Y, MIYAMOTO M, SUGIBAYASHI K, MORIMOTO Y: Drug permeation through the three layers of the human nail plate. J. Pharm. Pharmacol. (1999) 51:271-278.
  • PALMERI A, PICHINI S, PACIFICI R et al.: Drugs in nails: physiology, pharmacokinetics and forensic toxicology. Clin. Pharmacokinet. (2000) 38:95-110.
  • KOBAYASHI Y, KOMATSU T, SUMI M et al.: In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur. J. Pharm. Sci. (2004) 21:471-477.
  • HANEKE E, ROSEEUW D: The scope of onychomycosis: epidemiology and clinical features. Int. J. Dermatol. (1999) 38:7-12.
  • GIANNI C, MORELLI V, CERRI A et al.: Usefulness of histological examination for diagnosis of onychomycosis. Dermatology (2001) 202:283-288.
  • SUMMERBELL RC, COOPER E, BUNN U, JAMIESON F, GUPTA AK: Onychomycosis: a critical study of techniques and criteria for confirming the etiologic significance of nondermatophytes. Med. Mycol. (2005) 43:39-59.
  • PIERARD GE, QUATRESOOZ P, ARRESE JE: Spotlight on nail histomycology. Dermatol. Clin. (2006) 24:371-374.
  • BAKER SJ, HUI X, MAIBACH HI: Progress on new therapeutics for fungal nail infections. Ann. Rep. Med. Chem. (2005) 40:323-334.
  • PIERARD GE, PIERARD-FRANCHIMONT C, QUATRESOOZ P: Fungal thigmotropism in onychomycosis and in a clear hydrogel pad model. Dermatology (In press).
  • GHANNOUM MA, RICE LB: Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. (1999) 12:501-517.
  • VAN DE VELDE VJS, VAN PEER AP, HEYKANTS JJP et al.: Effects of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazole. Pharmacotherapy (1996) 16:424-428.
  • BARONE JA, MOSKOVITCH BL, GUARNIERI J et al.: Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob. Agents Chemother. (1998) 42:1862-1865.
  • MENICHETTI F, DEL FAVERO A, MARTINO P et al.: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin. Infect. Dis. (1998) 28:250-255.
  • GLASMACHER A, HALN C, MOLITOR E et al.: Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regiments using hydroxypropyl-β-cyclodextrin oral solution or coated-pellet capsules. Mycoses (1999) 42:591-600.
  • STEVENS DA: Itraconazole in cyclodextrin solution. Pharmacotherapy (1999) 19:603-611.
  • SUSILO R, KORTING HC, GREB W et al.: Nail penetration of sertaconazole with a sertaconazole-containing nail patch formulation. Am. J. Clin. Dermatol. (2006) 7:259-262.
  • FANG FC: Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. (1997) 99:2818-2825.
  • BAKER SJ, ZHANG YK, AKAMA T: Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. J. Med. Chem. (2006) 49:4447-4450.
  • GUPTA AK, LYNDE CW, KONNIKOV N: Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse for the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. (2001) 44:485-491.
  • POLACK A: The past, present and future of antimycotic combination therapy. Mycoses (1999) 42:355-370.
  • SANTOS DA, HAMDAN JS: In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. Med. Mycol. (2006) 44:357-362.
  • LECHA M, ALSINA M, TORRES RODRIGUES JM et al.: An open-label, multicenter study of the combination of amorolfine nail lacquer and oral itraconazole compared with itraconazole alone in the treatment of severe toenail onychomycosis. Curr. Ther. Res. (2002) 63:366-379.
  • BARAN R, SIGURGEIRSSON B, SIDOU F, KERROUCHE N, LECHA M: Efficacy and safety of amorolfine nail lacquer with oral terbinafine vs oral terbinafine alone in the treatment of onychomycosis with matrix involvement. J. Eur. Acad. Dermatol. Venereol. (2005) 19(Suppl 2):P16-P40.
  • SANTOS DA, HAMDAN JS: In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. Med. Mycol. (2006) 44:357-362.
  • BARCHIESI F, ARZENI D, CAMILETTI V et al.: In vivo activity of posaconazole against clinical isolates of dermatophytes. J. Clin. Microb. (2001) 39:4208-4209.
  • GUPTA AK, KOHLI Y, BATRA R: In vivo activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med. Mycol. (2005) 43:179-185.
  • ODDS F, AUSMA J, VAN GERVEN F et al.: In vitro and in vivo activities of the novel azole antifungal agent R126638. Antimicrob. Agents Chemother. (2004) 48:388-391.
  • VANDEN BOSSCHE H, AUSMA J, BOHETS H et al.: The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob. Agents Chemother. (2004) 48:3272-3278.
  • PIERARD-FRANCHIMONT C, AUSMA J, WOUTERS L et al.: Activity of the triazole antifungal R126638 as assessed by corneofungimetry. Skin Pharmacol. Physiol. (2006) 19:49-56.
  • GUPTA AK, TOMAS E: New antifungal agents. Dermatol. Clin. (2003) 21:565-576.
  • FUNG-TOME JC, HUEZKO E, MINASSIAN B, BONNER DP: In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agetns Chemother. (1998) 42:313-318.
  • GUPTA AK, LEONARDI C, STOLTZ RR et al.: A Phase I/II randomized, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J. Eur. Acad. Dermatol. (2005) 19:437-443.
  • PIERARD GE, ARRESE JE, QUATRESOOZ P, PIERARD-FRANCHIMONT C: Voriconazole (Vfen®). Rev. Med. Liège (2003) 58:351-355.
  • VAN LOO D: Voriconazole: an evaluation of activity and use. J. Infect. Dis. Pharmacother. (2003) 6:15-37.
  • FOSTEL JM, LARTEY PA: Emerging novel antifungal agents. Drug Discov. Today (2000) 5:25-32.
  • OHWADA J, TSUKAZAKI M, HAYASE T et al.: Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole. Bioorg. Med. Chem. Lett. (2003) 13:191-196.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.